Skip to main content
SpringerLink
Log in

Molecular Imaging of Vascular Inflammation, Atherosclerosis, and Thrombosis

  • Chapter
  • First Online:
Molecular and Translational Vascular Medicine

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 823 Accesses

Abstract

Molecular imaging provides unique means for detecting and quantifying biological processes in intact subjects. Started as a novel, emerging field only a decade ago, vascular molecular imaging is now at the footsteps of clinical practice and promises to drastically alter practice paradigms. Through detection of molecular and cellular processes involved in the pathogenesis of atherogenesis and other vascular diseases, molecular imaging can allow for early diagnosis and risk stratification based on objective assessment of dynamic biological processes occurring in a given individual. As a research tool, molecular imaging allows for longitudinal studies in the same subject and reduces the number of subjects needed in a given study to obtain interpretable data. By providing surrogate biological measures, molecular imaging may advance drug development and reduce the time required for evaluation of new drugs. In this chapter, we outline experimental imaging technologies and discuss the strengths and weaknesses associated with existent imaging platforms. We further describe molecular imaging approaches that involve detection of pathways associated with vascular diseases, including inflammation, extracellular matrix remodeling, and angiogenesis. We then review a number of clinical studies that involve molecular imaging for evaluation of atherosclerosis in specific patient populations. Much of the exciting potential of vascular molecular imaging has at least partially materialized and novel advances promise to expand its applications in vascular biology research and cardiovascular medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226–35.

    PubMed  CAS  Google Scholar 

  2. Prati F, Regar E, Mintz GS, et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur Heart J. 2010;31:401–15.

    PubMed  Google Scholar 

  3. Thakur ML, Lentle BC. Joint SNM/RSNA molecular imaging summit statement. J Nucl Med. 2005;46:11N–13N, 42N.

    Google Scholar 

  4. Franc BL, Acton PD, Mari C, Hasegawa BH. Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med. 2008;49:1651–63.

    PubMed  Google Scholar 

  5. Hwang AB, Franc BL, Gullberg GT, Hasegawa BH. Assessment of the sources of error affecting the quantitative accuracy of SPECT imaging in small animals. Phys Med Biol. 2008;53:2233–52.

    PubMed  Google Scholar 

  6. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 1:S15–29.

    PubMed  Google Scholar 

  7. Peng BH, Levin CS. Recent development in PET instrumentation. Curr Pharm Biotechnol. 2010;11:555–71.

    PubMed  CAS  Google Scholar 

  8. Botnar RM, Nagel E. Structural and functional imaging by MRI. Basic Res Cardiol. 2008;103:152–60.

    PubMed  Google Scholar 

  9. Winter PM, Caruthers SD, Lanza GM, Wickline SA. Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson. 2010;12:62.

    PubMed  Google Scholar 

  10. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med. 1998;4:623–6.

    PubMed  CAS  Google Scholar 

  11. Yu X, Song SK, Chen J, et al. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med. 2000;44:867–72.

    PubMed  CAS  Google Scholar 

  12. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A. 2007;104:961–6.

    PubMed  CAS  Google Scholar 

  13. Waters EA, Wickline SA. Contrast agents for MRI. Basic Res Cardiol. 2008;103:114–21.

    PubMed  CAS  Google Scholar 

  14. Lipinski MJ, Briley-Saebo KC, Mani V, Fayad ZA. “Positive contrast” inversion-recovery with ON[corrected]-resonant water suppression magnetic resonance imaging: a change for the better? J Am Coll Cardiol. 2008;52:492–4.

    PubMed  Google Scholar 

  15. Villanueva FS, Wagner WR. Ultrasound molecular imaging of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5 Suppl 2:S26–32.

    PubMed  CAS  Google Scholar 

  16. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med. 2003;9:123–8.

    PubMed  CAS  Google Scholar 

  17. Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1017–24.

    PubMed  CAS  Google Scholar 

  18. Chang K, Jaffer F. Advances in fluorescence imaging of the cardiovascular system. J Nucl Cardiol. 2008;15:417–28.

    PubMed  Google Scholar 

  19. Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23:313–20.

    PubMed  CAS  Google Scholar 

  20. Hyafil F, Cornily JC, Feig JE, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med. 2007;13:636–41.

    PubMed  CAS  Google Scholar 

  21. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.

    PubMed  CAS  Google Scholar 

  22. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med. 2005;352:2524–33.

    PubMed  CAS  Google Scholar 

  23. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47:C13–8.

    PubMed  CAS  Google Scholar 

  24. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–92.

    PubMed  CAS  Google Scholar 

  25. Sadeghi MM. The pathobiology of the vessel wall: implications for imaging. J Nucl Cardiol. 2006;13:402–14.

    PubMed  Google Scholar 

  26. Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788–91.

    PubMed  CAS  Google Scholar 

  27. Sadeghi MM, Schechner JS, Krassilnikova S, et al. Vascular cell adhesion molecule-1-targeted detection of endothelial activation in human microvasculature. Transplant Proc. 2004;36:1585–91.

    PubMed  CAS  Google Scholar 

  28. McAteer MA, Sibson NR, von Zur Muhlen C, et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med. 2007;13:1253–8.

    PubMed  CAS  Google Scholar 

  29. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005;96:327–36.

    PubMed  CAS  Google Scholar 

  30. Kelly KA, Nahrendorf M, Yu AM, Reynolds F, Weissleder R. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol. 2006;8:201–7.

    PubMed  Google Scholar 

  31. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504–11.

    PubMed  CAS  Google Scholar 

  32. Nahrendorf M, Keliher E, Panizzi P, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging. 2009;2:1213–22.

    PubMed  Google Scholar 

  33. Villanueva FS, Jankowski RJ, Klibanov S, et al. Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation. 1998;98:1–5.

    PubMed  CAS  Google Scholar 

  34. Kaufmann BA, Sanders JM, Davis C, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation. 2007;116:276–84.

    PubMed  CAS  Google Scholar 

  35. Kaufmann BA, Carr CL, Belcik JT, et al. Molecular imaging of the initial inflammatory response in atherosclerosis: implications for early detection of disease. Arterioscler Thromb Vasc Biol. 2010;30:54–9.

    PubMed  CAS  Google Scholar 

  36. Reynolds PR, Larkman DJ, Haskard DO, Hajnal JV, Kennea NL, George AJ, Edwards AD. Detection of vascular expression of E-selectin in vivo with MR imaging. Radiology. 2006;241:469–76.

    PubMed  Google Scholar 

  37. van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, Davis BG. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci U S A. 2009;106:18–23.

    PubMed  Google Scholar 

  38. Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, Steinman L. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J Neuroimmunol. 2000;104:1–9.

    PubMed  CAS  Google Scholar 

  39. Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI—initial results. Stroke. 2006;37:818–23.

    PubMed  Google Scholar 

  40. Demarco JK, Ota H, Underhill HR, et al. MR carotid plaque imaging and contrast-enhanced MR angiography identifies lesions associated with recent ipsilateral thromboembolic symptoms: an in vivo study at 3T. AJNR Am J Neuroradiol. 2010;31:1395–402.

    PubMed  CAS  Google Scholar 

  41. Mathiesen EB, Bonaa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation. 2001;103:2171–5.

    PubMed  CAS  Google Scholar 

  42. Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H. Ultrasonic echolucent carotid plaques predict future strokes. Circulation. 2001;104:68–73.

    PubMed  CAS  Google Scholar 

  43. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation. 1996;94:932–8.

    PubMed  CAS  Google Scholar 

  44. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49–57.

    PubMed  Google Scholar 

  45. Roberts AB, Lees AM, Lees RS, et al. Selective accumulation of low density lipoproteins in damaged arterial wall. J Lipid Res. 1983;24:1160–7.

    PubMed  CAS  Google Scholar 

  46. Rosen JM, Butler SP, Meinken GE, et al. Indium-111-labeled LDL: a potential agent for imaging atherosclerotic disease and lipoprotein biodistribution. J Nucl Med. 1990;31:343–50.

    PubMed  CAS  Google Scholar 

  47. Lees AM, Lees RS, Schoen FJ, et al. Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins. Arteriosclerosis. 1988;8:461–70.

    PubMed  CAS  Google Scholar 

  48. Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res. 1996;78:615–26.

    PubMed  CAS  Google Scholar 

  49. Iuliano L, Signore A, Vallabajosula S, et al. Preparation and biodistribution of 99m technetium labelled oxidized LDL in man. Atherosclerosis. 1996;126:131–41.

    PubMed  CAS  Google Scholar 

  50. Tsimikas S, Palinski W, Halpern SE, Yeung DW, Curtiss LK, Witztum JL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol. 1999;6:41–53.

    PubMed  CAS  Google Scholar 

  51. Tsimikas S, Shortal BP, Witztum JL, Palinski W. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol. 2000;20:689–97.

    PubMed  CAS  Google Scholar 

  52. Torzewski M, Shaw PX, Han KR, et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol. 2004;24:2307–12.

    PubMed  CAS  Google Scholar 

  53. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 2008;117:3206–15.

    PubMed  CAS  Google Scholar 

  54. Briley-Saebo KC, Cho YS, Shaw PX, et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol. 2011;57:337–47.

    PubMed  CAS  Google Scholar 

  55. Chang MK, Binder CJ, Miller YI, et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med. 2004;200:1359–70.

    PubMed  CAS  Google Scholar 

  56. Swirski FK, Pittet MJ, Kircher MF, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A. 2006;103:10340–5.

    PubMed  CAS  Google Scholar 

  57. Kircher MF, Grimm J, Swirski FK, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation. 2008;117:388–95.

    PubMed  Google Scholar 

  58. Hartung D, Petrov A, Haider N, et al. Radiolabeled monocyte chemotactic protein 1 for the detection of inflammation in experimental atherosclerosis. J Nucl Med. 2007;48:1816–21.

    PubMed  Google Scholar 

  59. Tang TY, Muller KH, Graves MJ, et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol. 2009;29:1001–8.

    PubMed  CAS  Google Scholar 

  60. Schmitz SA, Coupland SE, Gust R, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol. 2000;35:460–71.

    PubMed  CAS  Google Scholar 

  61. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation. 2001;103:415–22.

    PubMed  CAS  Google Scholar 

  62. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453–8.

    PubMed  CAS  Google Scholar 

  63. Schmitz SA, Taupitz M, Wagner S, Wolf KJ, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001;14:355–61.

    PubMed  CAS  Google Scholar 

  64. Trivedi RA, U-King-Im JM, Graves MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631–5.

    PubMed  Google Scholar 

  65. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol Imaging. 2006;5:85–92.

    PubMed  Google Scholar 

  66. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation. 2008;117:379–87.

    PubMed  CAS  Google Scholar 

  67. Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med. 2009;50:959–65.

    PubMed  CAS  Google Scholar 

  68. Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods. 2007;43:207–17.

    PubMed  Google Scholar 

  69. Greaves DR, Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res. 2005;46:11–20.

    PubMed  CAS  Google Scholar 

  70. Geng Y, Kodama T, Hansson GK. Differential expression of scavenger receptor isoforms during monocyte-macrophage differentiation and foam cell formation. Arterioscler Thromb. 1994;14:798–806.

    PubMed  CAS  Google Scholar 

  71. Kume N, Murase T, Moriwaki H, et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:322–7.

    PubMed  CAS  Google Scholar 

  72. Murase T, Kume N, Korenaga R, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:328–33.

    PubMed  CAS  Google Scholar 

  73. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334(Pt 1):9–13.

    PubMed  CAS  Google Scholar 

  74. Ishino S, Mukai T, Kuge Y, et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. J Nucl Med. 2008;49:1677–85.

    PubMed  CAS  Google Scholar 

  75. Li D, Patel AR, Klibanov AL, et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging. 2010;3:464–72.

    PubMed  CAS  Google Scholar 

  76. Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527–35.

    PubMed  Google Scholar 

  77. Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T. Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med Mol Imaging. 2003;30:267–73.

    PubMed  CAS  Google Scholar 

  78. Newsholme P, Curi R, Gordon S, Newsholme EA. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. Biochem J. 1986;239:121–5.

    PubMed  CAS  Google Scholar 

  79. Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T. Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med. 2004;45:455–60.

    PubMed  CAS  Google Scholar 

  80. Lederman RJ, Raylman RR, Fisher SJ, et al. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl Med Commun. 2001;22:747–53.

    PubMed  CAS  Google Scholar 

  81. Ogawa M, Ishino S, Mukai T, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med. 2004;45:1245–50.

    PubMed  CAS  Google Scholar 

  82. Tawakol A, Migrino RQ, Hoffmann U, et al. Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. 2005;12:294–301.

    PubMed  Google Scholar 

  83. Aziz K, Berger K, Claycombe K, Huang R, Patel R, Abela GS. Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography. Circulation. 2008;117:2061–70.

    PubMed  Google Scholar 

  84. Ogawa M, Magata Y, Kato T, et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006;47:1845–50.

    PubMed  CAS  Google Scholar 

  85. Zhao Y, Kuge Y, Zhao S, Strauss HW, Blankenberg FG, Tamaki N. Prolonged high-fat feeding enhances aortic 18F-FDG and 99mTc-annexin A5 uptake in apolipoprotein E-deficient and wild-type C57BL/6J mice. J Nucl Med. 2008;49:1707–14.

    PubMed  Google Scholar 

  86. Laurberg JM, Olsen AK, Hansen SB, et al. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation. Atherosclerosis. 2007;192:275–82.

    PubMed  CAS  Google Scholar 

  87. Laitinen I, Marjamaki P, Haaparanta M, et al. Non-specific binding of [18F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries. Eur J Nucl Med Mol Imaging. 2006;33:1461–7.

    PubMed  CAS  Google Scholar 

  88. Laitinen I, Saraste A, Weidl E, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging. 2009;2:331–8.

    PubMed  Google Scholar 

  89. Waldeck J, Hager F, Holtke C, et al. Fluorescence reflectance imaging of macrophage-rich atherosclerotic plaques using an alphavbeta3 integrin-targeted fluorochrome. J Nucl Med. 2008;49:1845–51.

    PubMed  Google Scholar 

  90. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation. 2002;105:939–43.

    PubMed  Google Scholar 

  91. Pasterkamp G, Fitzgerald PF, de Kleijn DP. Atherosclerotic expansive remodeled plaques: a wolf in sheep’s clothing. J Vasc Res. 2002;39:514–23.

    PubMed  Google Scholar 

  92. Kataoka T, Mathew V, Rubinshtein R, et al. Association of plaque composition and vessel remodeling in atherosclerotic renal artery stenosis: a comparison with coronary artery disease. JACC Cardiovasc Imaging. 2009;2:327–38.

    PubMed  Google Scholar 

  93. van Goor H, Melenhorst WB, Turner AJ, Holgate ST. Adamalysins in biology and disease. J Pathol. 2009;219:277–86.

    PubMed  Google Scholar 

  94. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–62.

    PubMed  CAS  Google Scholar 

  95. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J. 2007;21:3029–41.

    PubMed  CAS  Google Scholar 

  96. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol. 2006;4:101–16.

    PubMed  CAS  Google Scholar 

  97. Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg JO. Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2011;278:28–45.

    PubMed  CAS  Google Scholar 

  98. Back M, Ketelhuth DF, Agewall S. Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis. 2010;52:410–28.

    PubMed  Google Scholar 

  99. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res. 2006;69:625–35.

    PubMed  CAS  Google Scholar 

  100. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85:1–31.

    PubMed  CAS  Google Scholar 

  101. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005;102:15575–80.

    PubMed  CAS  Google Scholar 

  102. Funovics M, Weissleder R, Tung CH. Protease sensors for bioimaging. Anal Bioanal Chem. 2003;377:956–63.

    PubMed  CAS  Google Scholar 

  103. Deguchi JO, Aikawa M, Tung CH, et al. Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation. 2006;114:55–62.

    PubMed  Google Scholar 

  104. Kaijzel EL, van Heijningen PM, Wielopolski PA, et al. Multimodality imaging reveals a gradual increase in matrix metalloproteinase activity at aneurysmal lesions in live fibulin-4 mice. Circ Cardiovasc Imaging. 2010;3:567–77.

    PubMed  Google Scholar 

  105. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101:17867–72.

    PubMed  CAS  Google Scholar 

  106. van Duijnhoven SM, Robillard MS, Nicolay K, Grull H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med. 2011;52:279–86.

    PubMed  Google Scholar 

  107. Schafers M, Riemann B, Kopka K, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation. 2004;109:2554–9.

    PubMed  Google Scholar 

  108. Zhang J, Nie L, Razavian M, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation. 2008;118:1953–60.

    PubMed  CAS  Google Scholar 

  109. Tavakoli S, Razavian M, Zhang J, et al. Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler Thromb Vasc Biol. 2011;31:102–9.

    PubMed  CAS  Google Scholar 

  110. Razavian M, Zhang J, Nie L, et al. Molecular imaging of matrix metalloproteinase activation to predict murine aneurysm expansion in vivo. J Nucl Med. 2010;51:1107–15.

    PubMed  CAS  Google Scholar 

  111. Fujimoto S, Hartung D, Ohshima S, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol. 2008;52:1847–57.

    PubMed  CAS  Google Scholar 

  112. Ohshima S, Fujimoto S, Petrov A, et al. Effect of an antimicrobial agent on atherosclerotic plaques: assessment of metalloproteinase activity by molecular imaging. J Am Coll Cardiol. 2011;55:1240–9.

    Google Scholar 

  113. Ohshima S, Petrov A, Fujimoto S, et al. Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein e or low-density-lipoprotein receptor. J Nucl Med. 2009;50:612–7.

    PubMed  CAS  Google Scholar 

  114. Lancelot E, Amirbekian V, Brigger I, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol. 2008;28:425–32.

    PubMed  CAS  Google Scholar 

  115. Amirbekian V, Aguinaldo JG, Amirbekian S, et al. Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo. Radiology. 2009;251:429–38.

    PubMed  Google Scholar 

  116. Hyafil F, Vucic E, Cornily JC, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J. 2011;32:1561–71.

    PubMed  Google Scholar 

  117. Bazeli R, Coutard M, Duport BD, et al. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2011;45:662–8.

    Google Scholar 

  118. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1359–66.

    PubMed  CAS  Google Scholar 

  119. Sukhova GK, Zhang Y, Pan JH, et al. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111:897–906.

    PubMed  CAS  Google Scholar 

  120. Rodgers KJ, Watkins DJ, Miller AL, et al. Destabilizing role of cathepsin S in murine atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006;26:851–6.

    PubMed  CAS  Google Scholar 

  121. Weissleder R, Tung CH, Mahmood U, Bogdanov Jr A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17:375–8.

    PubMed  CAS  Google Scholar 

  122. Chen J, Tung CH, Mahmood U, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105:2766–71.

    PubMed  Google Scholar 

  123. Kim DE, Kim JY, Schellingerhout D, et al. Protease imaging of human atheromata captures molecular information of atherosclerosis, complementing anatomic imaging. Arterioscler Thromb Vasc Biol. 2010;30:449–56.

    PubMed  CAS  Google Scholar 

  124. Jaffer FA, Kim DE, Quinti L, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation. 2007;115:2292–8.

    PubMed  CAS  Google Scholar 

  125. Nahrendorf M, Waterman P, Thurber G, et al. Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol. 2009;29:1444–51.

    PubMed  CAS  Google Scholar 

  126. Jaffer FA, Vinegoni C, John MC, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118:1802–9.

    PubMed  Google Scholar 

  127. Sheth RA, Tam JM, Maricevich MA, Josephson L, Mahmood U. Quantitative endovascular fluorescence-based molecular imaging through blood of arterial wall inflammation. Radiology. 2009;251:813–21.

    PubMed  Google Scholar 

  128. Matter CM, Schuler PK, Alessi P, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95:1225–33.

    PubMed  CAS  Google Scholar 

  129. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249–56.

    PubMed  CAS  Google Scholar 

  130. Johnson LL, Schofield LM, Verdesca SA, et al. In vivo uptake of radiolabeled antibody to proliferating smooth muscle cells in a swine model of coronary stent restenosis. J Nucl Med. 2000;41:1535–40.

    PubMed  CAS  Google Scholar 

  131. Narula J, Petrov A, Bianchi C, et al. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab′)2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments. Circulation. 1995;92:474–84.

    PubMed  CAS  Google Scholar 

  132. Jimenez J, Donahay T, Schofield L, Khaw BA, Johnson LL. Smooth muscle cell proliferation index correlates with 111In-labeled antibody Z2D3 uptake in a transplant vasculopathy swine model. J Nucl Med. 2005;46:514–9.

    PubMed  CAS  Google Scholar 

  133. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010;9:804–20.

    PubMed  CAS  Google Scholar 

  134. Choi ET, Engel L, Callow AD, et al. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg. 1994;19:125–34.

    PubMed  CAS  Google Scholar 

  135. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203–6.

    PubMed  CAS  Google Scholar 

  136. Srivatsa SS, Fitzpatrick LA, Tsao PW, et al. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation. Cardiovasc Res. 1997;36:408–28.

    PubMed  CAS  Google Scholar 

  137. Sadeghi MM, Krassilnikova S, Zhang J, et al. Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation. 2004;110:84–90.

    PubMed  CAS  Google Scholar 

  138. Zhang J, Krassilnikova S, Gharaei AA, et al. Alphavbeta3-targeted detection of arteriopathy in transplanted human coronary arteries: an autoradiographic study. FASEB J. 2005;19:1857–9.

    PubMed  CAS  Google Scholar 

  139. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation. 2004;110:2032–8.

    PubMed  Google Scholar 

  140. Tenaglia AN, Peters KG, Sketch Jr MH, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J. 1998;135:10–4.

    PubMed  CAS  Google Scholar 

  141. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med. 2003;349:2316–25.

    PubMed  CAS  Google Scholar 

  142. Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054–61.

    PubMed  CAS  Google Scholar 

  143. Gossl M, Versari D, Hildebrandt HA, et al. Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis. JACC Cardiovasc Imaging. 2010;3:32–40.

    PubMed  Google Scholar 

  144. Calcagno C, Mani V, Ramachandran S, Fayad ZA. Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis. 2010;13:87–99.

    PubMed  Google Scholar 

  145. Kwon HM, Sangiorgi G, Ritman EL, et al. Adventitial vasa vasorum in balloon-injured coronary arteries: visualization and quantitation by a microscopic three-dimensional computed tomography technique. J Am Coll Cardiol. 1998;32:2072–9.

    PubMed  CAS  Google Scholar 

  146. Giannarelli C, Ibanez B, Cimmino G, et al. Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. JACC Cardiovasc Imaging. 2010;3:1256–64.

    PubMed  Google Scholar 

  147. Winter PM, Morawski AM, Caruthers SD, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation. 2003;108:2270–4.

    PubMed  CAS  Google Scholar 

  148. Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2103–9.

    PubMed  CAS  Google Scholar 

  149. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging. 2008;1:624–34.

    PubMed  Google Scholar 

  150. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation. 2003;107:455–60.

    PubMed  CAS  Google Scholar 

  151. Rodriguez-Porcel M, Cai W, Gheysens O, et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J Nucl Med. 2008;49:667–73.

    PubMed  Google Scholar 

  152. Boles KS, Schmieder AH, Koch AW, et al. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 2010;24:4262–70.

    PubMed  CAS  Google Scholar 

  153. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10:36–46.

    PubMed  CAS  Google Scholar 

  154. De Saint-Hubert M, Prinsen K, Mortelmans L, Verbruggen A, Mottaghy FM. Molecular imaging of cell death. Methods. 2009;48:178–87.

    PubMed  Google Scholar 

  155. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207–16.

    PubMed  CAS  Google Scholar 

  156. Smrz D, Draberova L, Draber P. Non-apoptotic phosphatidylserine externalization induced by engagement of glycosylphosphatidylinositol-anchored proteins. J Biol Chem. 2007;282:10487–97.

    PubMed  CAS  Google Scholar 

  157. Elliott JI, Surprenant A, Marelli-Berg FM, et al. Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes. Nat Cell Biol. 2005;7:808–16.

    PubMed  CAS  Google Scholar 

  158. Kolodgie FD, Narula J, Burke AP, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol. 2000;157:1259–68.

    PubMed  CAS  Google Scholar 

  159. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med. 2008;49 Suppl 2:81S–95.

    PubMed  CAS  Google Scholar 

  160. Kolodgie FD, Petrov A, Virmani R, et al. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin V: a technique with potential for noninvasive imaging of vulnerable plaque. Circulation. 2003;108:3134–9.

    PubMed  CAS  Google Scholar 

  161. Isobe S, Tsimikas S, Zhou J, et al. Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. J Nucl Med. 2006;47:1497–505.

    PubMed  CAS  Google Scholar 

  162. Johnson LL, Schofield L, Donahay T, Narula N, Narula J. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J Nucl Med. 2005;46:1186–93.

    PubMed  Google Scholar 

  163. Haider N, Hartung D, Fujimoto S, et al. Dual molecular imaging for targeting metalloproteinase activity and apoptosis in atherosclerosis: molecular imaging facilitates understanding of pathogenesis. J Nucl Cardiol. 2009;16:753–62.

    PubMed  Google Scholar 

  164. Tekabe Y, Li Q, Luma J, et al. Noninvasive monitoring the biology of atherosclerotic plaque development with radiolabeled annexin V and matrix metalloproteinase inhibitor in spontaneous atherosclerotic mice. J Nucl Cardiol. 2010;17:1073–81.

    PubMed  Google Scholar 

  165. Leon C, Nandan D, Lopez M, Moeenrezakhanlou A, Reiner NE. Annexin V associates with the IFN-gamma receptor and regulates IFN-gamma signaling. J Immunol. 2006;176:5934–42.

    PubMed  CAS  Google Scholar 

  166. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation. 2008;117:2938–48.

    PubMed  Google Scholar 

  167. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol. 2001;21:1618–22.

    PubMed  CAS  Google Scholar 

  168. Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–9.

    PubMed  Google Scholar 

  169. Zaheer A, Lenkinski RE, Mahmood A, Jones AG, Cantley LC, Frangioni JV. In vivo near-infrared fluorescence imaging of osteoblastic activity. Nat Biotechnol. 2001;19:1148–54.

    PubMed  CAS  Google Scholar 

  170. Aikawa E, Nahrendorf M, Figueiredo JL, et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007;116:2841–50.

    PubMed  CAS  Google Scholar 

  171. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–84.

    PubMed  CAS  Google Scholar 

  172. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938–49.

    PubMed  CAS  Google Scholar 

  173. Taillefer R, Edell S, Innes G, Lister-James J. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. J Nucl Med. 2000;41:1214–23.

    PubMed  CAS  Google Scholar 

  174. Bates SM, Lister-James J, Julian JA, Taillefer R, Moyer BR, Ginsberg JS. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med. 2003;163:452–6.

    PubMed  CAS  Google Scholar 

  175. Dunzinger A, Hafner F, Schaffler G, Piswanger-Soelkner JC, Brodmann M, Lipp RW. 99mTc-apcitide scintigraphy in patients with clinically suspected deep venous thrombosis and pulmonary embolism. Eur J Nucl Med Mol Imaging. 2008;35:2082–7.

    PubMed  Google Scholar 

  176. von Zur Muhlen C, von Elverfeldt D, Choudhury RP, et al. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging. 2008;7:59–67.

    Google Scholar 

  177. Klink A, Lancelot E, Ballet S, et al. Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe. Arterioscler Thromb Vasc Biol. 2010;30:403–10.

    PubMed  CAS  Google Scholar 

  178. Iwaki T, Ploplis VA, Castellino FJ. The hemostasis system in murine atherosclerosis. Curr Drug Targets. 2008;9:229–38.

    PubMed  CAS  Google Scholar 

  179. Botnar RM, Buecker A, Wiethoff AJ, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463–6.

    PubMed  Google Scholar 

  180. Spuentrup E, Buecker A, Katoh M, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005;111:1377–82.

    PubMed  CAS  Google Scholar 

  181. Sirol M, Fuster V, Badimon JJ, et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112:1594–600.

    PubMed  Google Scholar 

  182. Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18:1995–2005.

    PubMed  Google Scholar 

  183. Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res. 1999;94:271–305.

    PubMed  CAS  Google Scholar 

  184. Jaffer FA, Tung CH, Wykrzykowska JJ, et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation. 2004;110:170–6.

    PubMed  CAS  Google Scholar 

  185. Miserus RJ, Herias MV, Prinzen L, et al. Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc Imaging. 2009;2:987–96.

    PubMed  Google Scholar 

  186. Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A. 18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med. 2002;32:70–6.

    PubMed  Google Scholar 

  187. Tatsumi M, Cohade C, Nakamoto Y, Wahl RL. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology. 2003;229:831–7.

    PubMed  Google Scholar 

  188. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004;45:1816–21.

    PubMed  Google Scholar 

  189. Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005;46:1278–84.

    PubMed  Google Scholar 

  190. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.

    PubMed  CAS  Google Scholar 

  191. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818–24.

    PubMed  Google Scholar 

  192. Rudd JH, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–6.

    PubMed  Google Scholar 

  193. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825–31.

    PubMed  CAS  Google Scholar 

  194. Lee SJ, On YK, Lee EJ, Choi JY, Kim BT, Lee KH. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. J Nucl Med. 2008;49:1277–82.

    PubMed  CAS  Google Scholar 

  195. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med. 2009;50:563–8.

    PubMed  Google Scholar 

  196. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging. 2010;3:388–97.

    PubMed  Google Scholar 

  197. Kwee RM, Teule GJ, van Oostenbrugge RJ, et al. Multimodality imaging of carotid artery plaques: 18F-fluoro-2-deoxyglucose positron emission tomography, computed tomography, and magnetic resonance imaging. Stroke. 2009;40:3718–24.

    PubMed  Google Scholar 

  198. Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007;28:2243–8.

    PubMed  CAS  Google Scholar 

  199. Graebe M, Pedersen SF, Borgwardt L, Hojgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009;37:714–21.

    PubMed  CAS  Google Scholar 

  200. Khazen W, M’Bika JP, Tomkiewicz C, et al. Expression of macrophage-selective markers in human and rodent adipocytes. FEBS Lett. 2005;579:5631–4.

    PubMed  CAS  Google Scholar 

  201. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A. 2003;100:13531–6.

    PubMed  CAS  Google Scholar 

  202. Sadeghi MM, Glover DK, Lanza GM, Fayad ZA, Johnson LL. Imaging atherosclerosis and vulnerable plaque. J Nucl Med. 2010;51 Suppl 1:51S–65.

    PubMed  Google Scholar 

  203. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles – initial clinical experience. Radiology. 1998;207:799–808.

    PubMed  CAS  Google Scholar 

  204. Trivedi RA, Mallawarachi C, U-King-Im JM, et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26:1601–6.

    PubMed  CAS  Google Scholar 

  205. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009;53:2039–50.

    PubMed  CAS  Google Scholar 

  206. Fayad ZA, Razzouk L, Briley-Saebo KC, Mani V. Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still “rusty?”. J Am Coll Cardiol. 2009;53:2051–2.

    PubMed  Google Scholar 

  207. Vymazal J, Spuentrup E, Cardenas-Molina G. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697–704.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cardiovascular Medicine, Yale University School of Medicine and VA Connecticut Healthcare System, New Haven, CT, USA

    Dan Jane-Wit MD, PhD

  2. Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA

    Dan Jane-Wit MD, PhD

  3. Section of Cardiovascular Medicine, Yale University School of Medicine and VA Connecticut Healthcare System, West Haven, CT, 06516, USA

    Mehran M. Sadeghi MD

Authors
  1. Dan Jane-Wit MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehran M. Sadeghi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehran M. Sadeghi MD .

Editor information

Editors and Affiliations

  1. , The University of North Carolina, McAllister Heart Institute, 101 Manning Drive, Chapel Hill, 27599-7525, USA

    Jonathon W. Homeister

  2. , The University of North Carolina, McAllister Heart Institute, 103 Mason Farm Road, Chapel Hill, 27599-7525, USA

    Monte S. Willis

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jane-Wit, D., Sadeghi, M.M. (2012). Molecular Imaging of Vascular Inflammation, Atherosclerosis, and Thrombosis. In: Homeister, J., Willis, M. (eds) Molecular and Translational Vascular Medicine. Molecular and Translational Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-906-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-906-8_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-905-1

  • Online ISBN: 978-1-61779-906-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation